Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional) | RFA MD 22 004

Opportunity Information: Apply for RFA MD 22 004

Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional), Funding Opportunity Number RFA-MD-22-004, is a National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grant opportunity designed to push practical, commercializable solutions that measurably improve minority health and reduce or eliminate health disparities. The focus is on taking a technology, product, process, or service beyond an idea and into development with a clear path toward real-world use, especially in communities that experience disproportionate disease burden and poorer health outcomes. The opportunity sits within NIH's broader health mission and aligns with multiple activity areas listed in the announcement, including health, education, and food and nutrition, reflecting the reality that disparities are shaped by both clinical and non-clinical factors.

The core purpose of the FOA is to support small businesses that can build innovations that work in the settings where disparities occur. NIH is explicitly looking for solutions that are not only effective from a scientific or technical standpoint, but also affordable and culturally acceptable, which is a key distinction from many purely technology-driven programs. In practice, this means applicants are expected to think through adoption barriers up front: cost constraints, usability, language access, community trust, and fit with cultural practices and local care environments. The targeted outcomes are improvements in health for one or more NIH-defined population groups that experience health disparities, which commonly include racial and ethnic minority groups and other disparity populations recognized by NIH policy and research frameworks.

Mechanism-wise, this is an SBIR R43/R44 opportunity, meaning it supports the typical SBIR phased pathway. Phase I (R43) generally supports early-stage feasibility and proof-of-concept work, while Phase II (R44) supports further development, refinement, and steps needed to move toward commercialization and broader implementation. The announcement notes "Clinical Trial Optional," which indicates that applicants may propose clinical trials if they are appropriate for the stage and nature of the innovation, but a clinical trial is not automatically required. This flexibility is important for small businesses, because some disparity-reduction innovations are best validated through usability, implementation, or effectiveness studies that may or may not meet NIH's definition of a clinical trial, depending on how outcomes and interventions are structured.

Eligibility is limited to United States small business concerns, emphasizing the program's intent to stimulate domestic innovation and commercialization. Foreign institutions are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible. That said, the FOA leaves room for "foreign components" as defined in the NIH Grants Policy Statement, which can sometimes allow certain international elements if they are well-justified and permitted under NIH policy. In other words, the applicant organization must be a U.S. small business, and the project must be structured so that any non-U.S. involvement complies with NIH rules and does not constitute an ineligible non-domestic component.

From an administrative standpoint, this is a discretionary grant under NIH, and the original closing date listed for the opportunity was April 4, 2022, with a creation date of January 5, 2022. The announcement references multiple Assistance Listing (CFDA) numbers (93.233, 93.242, 93.279, 93.286, 93.307, 93.350, 93.837, 93.838, 93.839, 93.840, 93.847, 93.866), which signals that the participating NIH Institutes and Centers may span several biomedical and public health domains, and that projects could fit within a range of NIH portfolios so long as they directly address minority health and health disparities.

Overall, the FOA is best understood as a commercialization-oriented NIH research and development opportunity for U.S. small businesses that can deliver practical innovations tailored to disparity-affected communities. Competitive projects are likely to be those that demonstrate a credible technical plan, a clear commercialization pathway, and a thoughtful strategy for ensuring the solution is accessible, affordable, and acceptable to the populations it is meant to serve, with evaluation plans that can convincingly show impact on disparity-related outcomes.

• The National Institutes of Health in the education, food and nutrition, health sector is offering a public funding opportunity titled "Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.233, 93.242, 93.279, 93.286, 93.307, 93.350, 93.837, 93.838, 93.839, 93.840, 93.847, 93.866.
• This funding opportunity was created on 2022-01-05.
• Applicants must submit their applications by 2022-04-04. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: Small businesses.

Apply for RFA MD 22 004

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: